https://www.nature.com/articles/d41586-022-00562-0 [2] 抗耐药病原微生物（多药耐药菌、耐药支原体等）的新型抗生素药物开发。 [3] 经典名方《人参五味子汤》、《泻黄散》、《白术散》、《清宁散》、《三化汤》、《升陷汤》、《达原饮》、《当归补血汤》、等的工艺与质量标准开发。 [4] 中药同名同方药开发。 3.论文/著作/专利 第一作者(或通讯作者)在Journal of Medicinal Chemistry, European Journal of Medicinal Chemistry, Phytomedicine, Biomedicine& Pharmacotherapy, Food & Function, Journal of Functional Foods, RSC Advance, Journal of Sulfur Chemistry, Synthetic Communications,《中草药》,《中国中药杂志》,《中药材》,《中国抗生素杂志》等期刊发表SCI、EI、CSCD收录论文62篇，其中中科院1区Top期刊论文22篇，19篇IF＞7，ESI高被引论文2篇，ESI热点论文1篇，ESI总被引＞1300，5篇被引＞100，h-index=17，授权中国（38）、美国（47）、日本 （35）发明专利共计120件。参编国际出版商Elsevier Academic Press英文专著2部。 英文专著： [1] Oxazolidinone scaffolds in drug discovery and development, Privileged Scaffolds in Drug Discovery, Elsevier Academic Press, 2023, Pages 117-146, ISBN 9780443186110, (https://www.sciencedirect.com/science/article/pii/B9780443186110000358) [2] Verquvo, a First-in-Class Soluble Guanylate Cyclase (sGC) Stimulator for the Treatment of Heart Failure，Drug Discovery Stories, Elsevier Academic Press, 2024, In press 近期部分代表论文： [1]Discovery of Quaternized Pyridine-Thiazole-Pleuromutilin Derivatives with Broad Spectrum Antibacterial and Potent Anti-MRSA Activity. J. Med. Chem, 2023. 66(7), 5061-5078.（Highlighted Cover Article） [2] Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection, Eur. J. Med. Chem., 2024. 115979 [3] Design, synthesis, and evaluation of novel pleuromutilin aryl acrylate derivatives as promising broad-spectrum antibiotics especially for combatting multi-drug resistant gram-negative bacteria, Eur. J. Med. Chem., 2023. 115653. [4] A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects, Molecules 2023, 28(4), 1762. [5] Insights into stimuli-responsive diselenide bonds utilized in drug delivery systems for cancer therapy, Biomedicine & Pharmacotherapy, 2022, 155:113707 [6] From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin- Dependent Kinase (CDK) Inhibitors for Multiple Cancer Therapy. J. Med. Chem, 2022 65(9) , 6390-6418. [7] Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects. J. Med. Chem., 2022, 65 (10) , 7016-7043 [8] Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF). Biomedicine & Pharmacotherapy, 2022, 149:112894 [9] Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs. J. Med. Chem., 2021, 64 (15) ,10557-10580 [10] Overview of All-trans-Retinoic acid (ATRA) and Its Analogues: Structures, Activities, and Mechanisms in Acute Promyelocytic Leukaemia, Eur. J. Med. Chem., 2021.113451. [11] RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic. Eur. J. Med. Chem., 2021, 213: 113201. [12] Syringa microphylla Diels: A comprehensive review of its phytochemical, pharmacological, pharmacokinetic, and toxicological characteristics and an investigation into its potential health benefits. Phytomedicine, 2021,93:153770 [13] Foresight regarding drug candidates acting on the succinate-GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Biomedicine & Pharmacotherapy, 2021, 144:112298 [14] An Update Review of Emerging Small-Molecule Therapeutic Options for COVID-19. Biomedicine & Pharmacotherapy, 2021, 137:111313. | 
